DOCSLIB.ORG

Ep 2146997 B1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ep 2146997 B1 (19) TZZ __T (11) EP 2 146 997 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 491/048 (2006.01) A61K 31/4355 (2006.01) 10.11.2010 Bulletin 2010/45 A61P 3/04 (2006.01) A61P 25/18 (2006.01) A61P 25/22 (2006.01) A61P 25/28 (2006.01) (21) Application number: 08742647.4 (86) International application number: (22) Date of filing: 07.04.2008 PCT/US2008/004533 (87) International publication number: WO 2008/127585 (23.10.2008 Gazette 2008/43) (54) SUBSTITUTED FURO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS SUBSTITUIERTE FURO[2,3-B]PYRIDINDERIVATE ALS CANNABINOID-1- REZEPTORMODULATOREN DÉRIVÉS FURO[2,3-B]PYRIDINE SUBSTITUÉS UTILES EN TANT QUE MODULATEURS DU RÉCEPTEUR DES CANNABINOÏDES 1 (84) Designated Contracting States: • HALE, Jeffrey, J. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Rahway, New Jersey 07065-0907 (US) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • MADSEN-DUGGAN, Christina, B. RO SE SI SK TR Rahway, New Jersey 07065-0907 (US) • WALSH, Thomas, F. (30) Priority: 11.04.2007 US 922851 P Rahway, New Jersey 07065-0907 (US) • PERESYPKIN, Andrey, V. (43) Date of publication of application: Rahway, New Jersey 07065-0907 (US) 27.01.2010 Bulletin 2010/04 • HELMY, Roy Rahway, New Jersey 07065-0907 (US) (73) Proprietor: Merck Sharp & Dohme Corp. Rahway, NJ 07065 (US) (74) Representative: Buchan, Gavin MacNicol et al Merck & Co., Inc. (72) Inventors: European Patent Department • CLEMENTS, Matthew, J. Hertford Road Rahway, New Jersey 07065-0907 (US) Hoddesdon, Hertfordshire EN11 9BU (GB) • DEBENHAM, John, S. Rahway, New Jersey 07065-0907 (US) (56) References cited: WO-A1-2005/115977 US-B2- 7 091 216 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 146 997 B1 Printed by Jouve, 75001 PARIS (FR) EP 2 146 997 B1 Description BACKGROUND OF THE INVENTION 5 [0001] Marijuana (Cannabis sativa L.) and its derivatives have been used for centuries for medicinal and recreational purposes. A major active ingredient in marijuana and hashish has been determined to be ∆9-tetrahydrocannabinol (∆9-THC). Detailed research has revealed that the biological action of ∆9-THC and other members of the cannabinoid family occurs through two G-protein coupled receptors termed CB1 and CB2. The CB1 receptor is primarily found in the central and peripheral nervous systems and to a lesser extent in several peripheral organs. The CB2 receptor is 10 found primarily in lymphoid tissues and cells. Three endogenous ligands for the cannabinoid receptors derived from arachidonic acid have been identified (anandamide, 2-arachidonoyl glycerol, and 2-arachidonyl glycerol ether). Each is an agonist with activities similar to ∆9-THC, including sedation, hypothermia, intestinal immobility, antinociception, an- algesia, catalepsy, anti-emesis, and appetite stimulation. [0002] There are at least three CB1 modulators characterized as inverse agonists/antagonists, ACOMPLIA (rimona- 15 bant, N-(1-piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, SR141716A), and 3-(4-chlorophenyl-N’-(4-chlorophenyl)sulfonyl-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide (SLV-319), and taranabant, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)-2- pyridinyl]oxy]propanamide, in clinical development for treatment of eating disorders and/or smoking cessation at this time. There still remains a need for potent low molecular weight CB1 modulators that have pharmacokinetic and phar- 20 macodynamic properties suitable for use as human pharmaceuticals. [0003] Furopyridine compounds are disclosed in US 2006/0046977, EP 0 737 685, JP 2006-45 220, JP 7-76586, WO 2004/014375, WO 2004/096130, WO 2005/009389, WO 2005/061476, WO 2005/067900, WO 2006/013095, and WO 2006/030031. Furopyridine CB1 antagonists/inverse agonists are disclosed in WO 04/012671 and US 7,091,216. 25 SUMMARY OF THE INVENTION [0004] The present invention is concerned with novel furo pyridines of structural Formula I: 30 35 40 and pharmaceutically acceptable salts thereof which are modulators of and, in particular, antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention or suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. In one aspect, the invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer’s 45 disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, and complications associated therewith, including left ventricular hypertrophy, as well as the treatment of asthma, constipation, chronic intestinal 50 pseudo-obstruction, and cirrhosis of the liver. [0005] The present invention is also concerned with treatment of these conditions, and the use of compounds of the present invention for manufacture of a medicament useful in treating these conditions. The present invention is also concerned with treatment of these conditions through a combination of compounds of formula I and other currently available pharmaceuticals. 55 [0006] The invention is also concerned with pharmaceutical formulations comprising one of the compounds as an active ingredient, as well as processes for preparing the compounds of this invention. 2 EP 2 146 997 B1 BRIEF DESCRIPTION OF THE DRAWINGS [0007] 5 FIG. 1 is the X-ray diffraction (XRPD) pattern for the anhydrous free base crystalline 1:1 ethanolate polymorphic Form I of Example 3. FIG. 2 is the Thermogravimetry analysis (TGA) curve for the anhydrous free base crystalline 1:1 ethanolate poly- morphic Form I of Example 3. FIG. 3 is the Differential scanning calorimetry (DSC) curve for the anhydrous free base crystalline 1:1 ethanolate 10 polymorphic Form I of Example 3. DETAILED DESCRIPTION OF THE INVENTION [0008] The compounds of the present invention are represented by the compound of structural formula I: 15 20 25 or a pharmaceutically acceptable salt thereof, wherein: R1 is selected from: (1) phenyl, 30 (2) heteroaryl, (3) -C(O)Ra, (4) -C(O)ORa, (5) -C(O)NRbRc, and a (6) -S(O)2R , 35 wherein each phenyl and heteroaryl is unsubstituted or substituted with one to four substituents independently selected b c from -OH, -C1-6alkyl, and halogen, and wherein R and R together with the atoms to which they are attached may form a 4-10 membered aromatic or non-aromatic mono- or bicyclic ring, wherein the 4-10 membered ring is unsubstituted or substituted with one to four substituents independently selected from -OH, -C1-6alkyl, and halogen; 40 R2 is selected from: (1) C1-10alkyl, (2) C3-10cycloalkyl, (3) cycloheteroalkyl, 45 (4) phenyl, (5) heteroaryl, (6) -C(O)C1-10alkyl, (7) -C(O)ORa, b (8) -C(O)N(R )2, 50 b (9) -N(R )2, and d (10) -NR C(O)C1-10alkyl, wherein each alkyl, cycloalkyl, cycloheteroalkyl, phenyl and heteroaryl is unsubstituted or substituted with one to four substituents independently selected from -OH, C1-6alkyl, and oxo; 55 R3 is selected from: (1) hydrogen, (2) C1-10alkyl, 3 EP 2 146 997 B1 (3) halogen, (4) -CN, (5) -CF3, (6) -OCF3, 5 (7) -C(O)C1-4alkyl, (8) -C(O)OC1-4alkyl, (9) -OC1-4alkyl, and (10) -SC1-4alkyl; 10 R4 is selected from: (1) pyrazole, (2) oxadiazole, (3) triazole, 15 (4) isoxazole, (5) isothiazole, and (6) thiadiazole, wherein each pyrazole, oxadiazole, triazole, isoxazole, isothiazole and thiadiazole is unsubstituted or substituted with one or three substituents selected from R6 and R7; 20 R5 is selected from: (1) hydrogen, (2) C1-10alkyl, (3) halogen, 25 (4) -CN, (5) -CF3, (6) -OCF3, (7) -C(O)C1-4alkyl, (8) -C(O)OC1-4alkyl, 30 (9) -OC1-4alkyl, and (10) -SC1-4alkyl; R6 is selected from: 35 (1) hydrogen, (2) C1-10alkyl, (3) halogen, (4) -CN, (5) -C(O)C1-6alkyl, 40 (6) -OC1-6alkyl, (7) -OCF3, and (8) -SC1-6alkyl; R7 is selected from: 45 (1) hydrogen, (2) C1-6alkyl, and (3) C(O)C1-10alkyl; 50 Ra is selected from: (1) C1-6alkyl, and (2) C3-7cycloalkyl, 55 wherein each alkyl and cycloalkyl is unsubstituted or substituted with one to four substituents independently selected from -OH, -C1-6alkyl, and halogen; Rb is selected from: 4 EP 2 146 997 B1 (1) hydrogen, (2) C1-6alkyl, and (3) phenyl, 5 wherein each alkyl and phenyl is unsubstituted or substituted with one to four substituents independently selected from -OH, -C1-6alkyl, and halogen; Rc is selected from: (1) C1-6alkyl, and 10 (2) phenyl, wherein each alkyl and phenyl is unsubstituted or substituted with one to four substituents independently selected from -OH, -C1-6alkyl, and halogen; and Rd is selected from: 15 (1) hydrogen, and (2) C1-6alkyl; wherein each alkyl is unsubstituted or substituted with one to four substituents independently selected from -OH, 20 -C1-6alkyl, and halogen. [0009] In one embodiment of the present invention, R1 is selected from: phenyl, heteroaryl, - C(O)Ra, -C(O)ORa,-C b c a (O)NR R , and -S(O)2R , wherein each phenyl and heteroaryl is unsubstituted or substituted with one to four substituents b c independently selected from -OH, -C1-6alkyl, and halogen, and wherein R and R together with the atoms to which they are attached may form a 4-10 membered aromatic or non-aromatic mono- or bicyclic ring, wherein the 4-10 membered 25 ring is unsubstituted or substituted with one to four substituents independently selected from -OH, -C1-6alkyl, and halogen, provided that both Rb and Rc are not phenyl.
Load more

Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • 1 441 702 B1
    (19) TZZ__Z _T (11) EP 1 441 702 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4045 (2006.01) A61P 25/20 (2006.01) 10.05.2017 Bulletin 2017/19 A61K 9/20 (2006.01) (21) Application number: 02760523.7 (86) International application number: PCT/IL2002/000662 (22) Date of filing: 12.08.2002 (87) International publication number: WO 2003/015690 (27.02.2003 Gazette 2003/09) (54) METHOD FOR TREATING PRIMARY INSOMNIA VERFAHREN ZUR BEHANDLUNG PRIMÄRER INSOMNIA METHODE DE TRAITEMENT DE L’INSOMNIE PRIMAIRE (84) Designated Contracting States: • ROTH T ET AL: "Consensus for the AT BE BG CH CY CZ DE DK EE ES FI FR GB GR pharmacological management of insomnia in th IE IT LI LU MC NL PT SE SK TR enew millennium", INTERNATIONAL JOURNAL Designated Extension States: OF CLINICAL PRACTICE, MEDICON LT LV RO SI INTERNATIONAL, ESHER, GB, vol. 55, no. 1, 1 January 2001 (2001-01-01), page 10PAGES, (30) Priority: 14.08.2001 IL 14490001 XP002990688, ISSN: 1368-5031 • PERLIS M L ET AL: "Psychophysiological (43) Date of publication of application: insomnia: the behavioural model and a 04.08.2004 Bulletin 2004/32 neurocognitive perspective", JOURNAL OF SLEEP RESEARCH, BLACKWELL SCIENTIFIC, (60) Divisional application: OXFORD, GB, vol. 6, 1 January 1997 (1997-01-01), 16172415.8 / 3 103 443 pages 179-188, XP002990686, ISSN: 0962-1105, DOI: DOI:10.1046/J.1365-2869.1997.00045.X (73) Proprietor: NEURIM PHARMACEUTICALS (1991) • SILVA J A C E ET AL: "Special report from a LIMITED symposium held by the WHO and the World Tel Aviv 69710 (IL) Federation of sleep research societies: an overview of insomnias and related disorders - (72) Inventor: ZISAPEL, Nava recognition, epidemiology and rational 69355 Tel Aviv (IL) management", SLEEP, ALLEN PRESS, LAWRENCE, KS,US, vol.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,365,521 B2 Blackburn Et Al
    USOO9365521B2 (12) United States Patent (10) Patent No.: US 9,365,521 B2 Blackburn et al. (45) Date of Patent: Jun. 14, 2016 (54) NON-HYGROSCOPICSALTS OF 5-HT, 5,178,786 A 1/1993 Jahnke et al. AGONSTS 5,247,080 A 9/1993 Berger et al. 5,275,915 A 1/1994 Kojima et al. 5,387,685 A 2f1995 Powell et al. (75) Inventors: Anthony C. Blackburn, San Diego, CA 5,397.793 A 3, 1995 Shaber et al. (US); Yun Shan, San Diego, CA (US); 5,412,119 A 5/1995 Brussee et al. Anna Shifrina, San Diego, CA (US); 5,422,355 A 6/1995 White et al. Scott Stirn, San Diego, CA (US) 5,691.362 A 11/1997 McCormicket al. 5,750,520 A 5/1998 Danilewicz et al. (73) Assignee: Arena Pharmaceuticals, Inc., San 5,856.5035,795,895 A 8,1/1999 1998 AnchAS al. Diego, CA (US) 5,861,393 A 1/1999 Danilewicz et al. 5,908,830 A 6/1999 Smith et al. (*) Notice: Subject to any disclaimer, the term of this 5,925,651 A 7/1999 Hutchinson patent is extended or adjusted under 35 3. A 3: As al U.S.C. 154(b) by 567 days. 5,958,943- 4 A 9/1999 Laufera etca. al. 6,087,346 A 7/2000 Glennon et al. (21) Appl. No.: 13/820,095 6,218,385 B1 4/2001 Adam et al. 6,900,313 B2 5/2005 Wasserscheid et al. (22) PCT Filed: Aug. 31, 2011 6,953,787 B2 * 10/2005 Smith .................
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Ep 2089382 B1
    (19) TZZ Z¥ _T (11) EP 2 089 382 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 401/14 (2006.01) C07D 413/14 (2006.01) 24.10.2012 Bulletin 2012/43 C07D 471/04 (2006.01) C07D 487/04 (2006.01) C07D 491/048 (2006.01) C07D 491/052 (2006.01) (2006.01) (2006.01) (21) Application number: 07862400.4 C07D 495/04 A61K 31/551 A61P 3/04 (2006.01) A61P 25/20 (2006.01) C07D 403/14 (2006.01) (22) Date of filing: 30.11.2007 (86) International application number: PCT/US2007/024690 (87) International publication number: WO 2008/069997 (12.06.2008 Gazette 2008/24) (54) SUBSTITUTED DIAZEPAN COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS SUBSTITUIERTE DIAZEPANVERBINDUNGEN ALS OREXIN-REZEPTOR-ANTAGONISTEN ANTAGONISTES DES RÉCEPTEURS DE L’OREXINE SOUS FORME DE COMPOSÉS DE DIAZÉPANE SUBSTITUÉS (84) Designated Contracting States: • COX, Christopher D. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Rahway, NJ 07065-0907 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • MERCER, Swati P. SI SK TR Rahway, NJ 07065-0907 (US) Designated Extension States: • ROECKER, Anthony J. HR RS Rahway, NJ 07065-0907 (US) (30) Priority: 01.12.2006 US 872393 P (74) Representative: Buchan, Gavin MacNicol 16.07.2007 US 959742 P Merck Sharp & Dohme Limited European Patent Department (43) Date of publication of application: Hertford Road 19.08.2009 Bulletin 2009/34 Hoddesdon Hertfordshire EN11 9BU (GB) (60) Divisional application: 11177692.8 / 2 392 572 (56) References cited: EP-A- 0 794 178 WO-A-03/041711 (73) Proprietor: Merck Sharp & Dohme Corp.
    [Show full text]
  • List of Withdrawn Drugs
    List of withdrawn drugs WRITEN BY LAIMA JONUSIENE To prove that the drug companies make mistakes with our lives we publish this list. Drugs are rushed onto the market for profit. The testing of the drugs is on the major indication. Side effects are NOT tested pre and post. Side effects are observed NOT tested. The expense of pre and post side effect testing is astounding. So it is not done. Side effects are then seen in the public use and a drug is removed from the market after killing or hurting people. There is a special law that prohibits you from suing a drug company for damages unless you can prove they knew it was harmful and sold it anyway. This means there is even less need to test side effects and or report them during the testing process. https://www.youtube.com/watch?v=h7Sd0uBc6eE - How a drug pill is brought to the market. Some drugs have been withdrawn from the market because of risks to the patients. Usually this has been prompted by unexpected adverse effects that were not detected during Phase III clinical trials and were only apparent from postmarketing surveillance data from the wider patient community. This list is not limited to drugs that were ever approved by the FDA. Some of them (Lumiracoxib, Rimonabant, Tolrestat, Ximelagatran and Zimelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the U.S., when side effects became clear and their developers pulled them from the market. Likewise LSD was never approved for marketing in the U.S.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Predicting the Function of Drug-Like Molecules Methods and Applications
    Predicting the function of drug-like molecules methods and applications Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by Hao Wang from Liupanshui, Guizhou province, People’s Republic of China January 2017 Diese Arbeit wurde in dem Zeitraum von November 2012 bis Januar 2017 unter der Leitung von Prof. Dr. Ernst Walter Knapp am Institute für Chemie und Biochemie der Freien Universität Berlin im Fachbereich Biologie, Chemie und Pharmazie durchgeführt. 1. Gutacher: Prof. Dr. Ernst-Walter Knapp 2. Gutacher: Prof. Dr. Gerhard Wolber Disputation am ___16. 3. 2017_________ Statutory Declaration I hereby testify that this thesis is the result of my own work and research, except for any explicitly referenced material, whose source is listed in the bibliography. This work contains material that is the copyright property of others, which must not be reproduced without the permission of the copyright own. Acknowledgement First of all, I would like to thank Prof. Dr. Ernst Walter Knapp, China Scholarship Council, Free University of Berlin and Xiamen University for giving me this precious opportunity to study in Germany. I very much appreciate the supervision of Prof. Dr. Ernst Walter Knapp and valuable discussions during my doctoral work. In addition, I would also like to thank Dr. Bentzien Jörg and Dr. Ingo Mugge in Boehringer-Ingelheim group for their cooperation and valuable suggestions for my research projects. I am thankful for the support and great help of my colleagues in AG Knapp during my doctoral studies.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • Computational Identification of a Phospholipidosis Toxicophore Using
    Bioorganic & Medicinal Chemistry 22 (2014) 6706–6714 Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry journal homepage: www.elsevier.com/locate/bmc Computational identification of a phospholipidosis toxicophore using 13C and 15N NMR-distance based fingerprints q Svetoslav H. Slavov a, Jon G. Wilkes a, Dan A. Buzatu a, Naomi L. Kruhlak b, James M. Willard b, ⇑ Joseph P. Hanig b, Richard D. Beger a, a Division of Systems Biology, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Rd., Jefferson, AR 72079, USA b Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA article info abstract Article history: Modified 3D-SDAR fingerprints combining 13C and 15N NMR chemical shifts augmented with inter-atomic Received 25 June 2014 distances were used to model the potential of chemicals to induce phospholipidosis (PLD). A curated Revised 13 August 2014 dataset of 328 compounds (some of which were cationic amphiphilic drugs) was used to generate Accepted 18 August 2014 3D-QSDAR models based on tessellations of the 3D-SDAR space with grids of different density. Composite Available online 27 August 2014 PLS models averaging the aggregated predictions from 100 fully randomized individual models were gen- erated. On each of the 100 runs, the activities of an external blind test set comprised of 294 proprietary Keywords: chemicals were predicted and averaged to provide composite estimates of their PLD-inducing potentials Phospholipidosis (PLD+ if PLD is observed, otherwise PLD ). The best performing 3D-QSDAR model utilized a grid with a Toxicophore À Fingerprint density of 8 ppm  8 ppm in the C–C region, 8 ppm  20 ppm in the C–N region and 20 ppm  20 ppm in Quantitative spectral data–activity the N–N region.
    [Show full text]
  • Doping Im Sport W.Schänzer Institut Für Biochemie Der Deutschen Sporthochschule Köln
    Skript 8.9.2001 Doping im Sport W.Schänzer Institut für Biochemie der Deutschen Sporthochschule Köln Inhalt Seite Einleitung 2 Doping-Definition 2 Stimulantien 5 Amphetamin 6 Coffein 8 Ecstasy 9 Bromantan 10 Narkotika 12 Morphin 12 Anabole Wirkstoffe 15 Anabolika (anabol androgene Steroidhormone) 15 Wirkungen des Testosterons 17 Nebenwirkungen von Anabolika 19 Endokrines System 21 ß2-Agonisten 24 Diuretika 26 Peptidhormone und Analoge 27 HCG ('Schwangerschaftshormon') 28 EPO (Erythropoietin) 29 HGH (Wachstumshormon) 31 Verbotene Methoden 33 Blutdoping 33 Manipulationen (pharmakol., chem., phys.) 35 Plasmaexpander und künstliche Sauerstoffträger 35 Eingeschränkt zugelassene Wirkstoffe 37 Cannabis 37 Lokalanästhetika 39 Corticosteroide 40 Beta-Blocker 42 Kreatin - Doping oder Substitution? 43 Ausführliche Dopinglisten 44 Literatur 48 2 Doping im Sport 1 Einleitung Die Verbesserung der körperlichen Leistungsfähigkeit unter Zuhilfenahme von pharmakologischen Wirkstoffen ist sicherlich ein alter Wunschtraum der Menschheit. Hierbei sind wirksame Substanzen, die aus pflanzlichen Naturstoffen isoliert bzw. zu medizinischen Zwecken synthetisiert wurden, um entsprechende Krankheitszustände zu heilen, immer wieder verwendet worden. Bereits in der Antike wurden bei Sportwettkämpfen stimulierende Substanzen eingesetzt, um Vorteile im Wettkampf zu erzielen. Inwieweit in der ersten Hälfte des 20. Jahrhunderts mit Wiederbeginn der Olympischen Spiele bis Ende der 60er Jahre Dopingsubstanzen zur Leistungssteigerung im Sport eingesetzt wurden, kann nur vermutet werden. Auf jeden Fall gab es noch keine Regeln, die Doping einschränkten bzw. verboten. Nachdem es in den 60er Jahren zu einigen Todesfällen im Radrennsport, insbesondere in Verbindung mit der Einnahme von Stimulanzien aus der Reihe der Amphetamine, gekommen war, wurden von den Sportverbänden Anti-Doping- Regeln aufgestellt. Bekannte Todesfälle waren z.B. die des Radfahrers Tom Simpson, der 1967 während der Tour de France tödlich zusammenbrach.
    [Show full text]